French Pleodrug for Rare Neurological Disease opens up phase III trial in US

27/04/2016 - 2 minutes

Pharnext is opening their first US study sites for a phase III trial in a rare neuropathy – a milestone in the development of Pharnext’s leading candidate.

pharnext_pxt3003_charcot_marie_tooth_cmt1aBased in Paris (France), Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease.

Pharnext uses network pharmacology to discover synergistic combinations of drugs (Pleodrugs) that can have a therapeutic effect in a given disease. As the components drugs are already approved, development is faster – meaning bypassing phase I trials is possible.

Pharnext’s most advanced pleodrug is PXT3003. It has already gone through phase II trials, obtaining good results and working as a proof of concept for the Pleotherapy platform.

pharnext_pxt3003_synergy_pleodrug_pleotheraphy
Pleotherapy, Pharnext’s R&D platform to create combination drugs (Source: Pharnext)

PXT3003 is now in phase III trials (PLEO-CMT), which expects to enroll 300 patients with Charcot-Marie-Tooth Disease Type 1A (CMT1A). Enrolment will progress during 2016, with the first US site now being opened in Saint-Louis University (Missouri).

This disease is caused by a rare genetic mutation (PMP 22 duplication) that leads to degradation of the neuronal sheath (myelin). As this happens, patients suffer from progressive muscle atrophy of legs and arms.

Related Content

PPXT3003 acts by inhibiting the overexpression in the PMP22 gene, but it also protects the peripheral nerves, muscle cells and neuromuscular junctions.

pharnext_pxt3003_pleodrug_myelin_cmt1a
Mechanisms of action of PXT3003 in Charcot-Marie-Tooth type 1A disease. (Source: Pharnext)

The candidate is a combinations of a muscle relaxant prescribed for disorders like multiple sclerosis (baclofen), an opioid antagonist to treat addictions (naltrexone hydrochloride) and D-sorbitol, a common sweetener.

Pharnext’s platform has already spawned a second candidate (PXT864), which is in phase II trials for Alzheimer’s disease after promising preclinical results (published last year).

The Pleotherapy platform is getting good results, which in the future could mean quick development of therapies for a range of neurological diseases.


Featured image credit: Pharnext

 

ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member